Notably, expression of TGFβ-associated myoCAF ECM genes is one of the strongest predictors of immunotherapy failure, highlighting the ability of myoCAF to create an immunosuppressive tumor microenvironment (8–12). The gene discussed is TGFB1; the disease is neoplasm.